Anti-CD25 therapy impairs donor-specific Th1 and Th2 cytokine-producing peripheral blood cells after clinical heart transplantation.
van Besouw
N M
NM
Department of Internal Medicine, University Hospital Rotterdam-Dijkzigt, Rotterdam, The Netherlands. vanbesouw@inw1.azr.nl
Balk
A H M M
AH
van Vliet
M
M
van der Meide
P H
PH
Maat
A P W M
AP
van Gelder
T
T
Baan
C C
CC
Weimar
W
W
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000097:blood; D000077561:Daclizumab; D004305:Dose-Response Relationship, Drug; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D017710:Lymphocyte Transfusion; D010919:Placebos; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology*; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016207:Cytokines; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D010919:Placebos; D015375:Receptors, Interleukin-2; D007371:Interferon-gamma; D000077561:Daclizumab